The age-specific rates of new clinically recorded fertility problems also were assessed in women with undiagnosed and diagnosed CD and in women with symptomatic celiac disease. These rates then were compared with the rates in women

without CD, and IRRs (95% CIs) were LGK-974 chemical structure calculated in a similar fashion as described earlier. Finally, the National Institute for Health and Clinical Excellence recommends that women with fertility problems should be screened for CD.30 Therefore, women are more likely to be screened for CD if they report a fertility problem. To assess this potential ascertainment of CD in relation to fertility problems we assessed the timing of new clinically recorded fertility problems in women in relation to their CD diagnosis to calculate the time difference between the 2 events. To increase the specificity of our CD definition, we restricted it to include

only women who had both a read code for CD and a gluten-free prescription. Age-specific rates of new clinically recorded fertility problems were recalculated in women with CD and in women without CD based on this definition. Ethical approval for this study was obtained from The Health Improvement Network Scientific Research Committee (EPIC Data Company) (reference number 11-027A). Of the total population Venetoclax mouse of 2,426,225 potentially fertile women contributing 15,236,530 years of follow-up time, 6506 (0.3%) women had a diagnosis of CD. The median follow-up time in the women with CD and in the women without CD was 6.5 person-years (interquartile range [IQR], 3.1–11.4) and 4.6 person-years (IQR, 2.4–9.0), Ponatinib chemical structure respectively.

The mean age at the first clinically recorded fertility problem was slightly higher in women with CD compared with women without CD (mean difference, 0.61; 95% CI, -0.13 to 1.34; P = .107), however, this difference was not statistically significant ( Table 1). Women with CD were more affluent compared with women without CD (25.8% compared with 20.9%, respectively, in quintile 1) and also more likely to be underweight (5.7% in women with CD compared with 3.3% in women without CD). The prevalence of smoking also was slightly lower in women with CD compared with women without CD (12.3% vs 17.0%; P < .001). In addition, women with CD also had a higher prevalence of other autoimmune diseases compared with the non-CD group (P for all comorbidities < .001). Of the 6506 women with CD, 290 (4.4%) had clinically recorded fertility problems, and of the 2,419,718 women without CD, 98,366 (4.1%) had clinically recorded fertility problems. When all codes relating to fertility problems appearing in women’s primary care records were assessed, there was no statistically significant difference in the distribution of drug treatment, investigations, interventions, referrals, or diagnoses between women with and without CD (Supplementary Table 1).